Feb 18 (Reuters) - Eli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed ...
After months of discussion, President Donald Trump’s new direct-to-consumer pharmaceutical site, TrumpRx, officially launched ...
Late last year, Lilly was the first pharmaceutical stock to reach a $1 trillion valuation.
Combination ixekizumab plus tirzepatide outperformed ixekizumab monotherapy for the treatment of both psoriasis and ...
The results of 2 recent clinical trials combining the GLP-1 drug and the biologic reinforce the benefits of treating obesity ...
With their blockbuster obesity drugs, Eli Lilly and Novo Nordisk have uncovered a variety of ailments the incretin treatments can combat. | Six weeks after Eli Lilly revealed the success of phase 3b ...
15d
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...
Eli Lilly (LLY) stock is in focus as Zepbound succeeds in a late-stage trial for patients with plaque psoriasis. Read more ...
PHOENIX, AZ - February 02, 2026 - PRESSADVANTAGE - Phoenix NP, a women-focused telehealth medical practice based in ...
Zepbound (tirzepatide) is a brand-name medication prescribed for weight management and to treat obstructive sleep apnea in certain adults. Zepbound comes as a solution for injection under the skin ...
Zepbound is a prescription drug used to help with weight loss and sleep apnea in certain adults. The starting dosage for weight loss and sleep apnea is 2.5 mg injected once weekly for 4 weeks. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results